Bogwood
$STAA I think most "next quarter" traders don't understand this earnings call implications for evo+ sell-in rates. More color was given on the Stifel conference yesterday, and this is part of the schizo giga thesis that could easily re-rate us to $50 by 1Q27 and beyond.
If you're new, this is the core of what Alcon saw in a potential acquisition: China's asp could easily be doubled with no impact to consumer price paid, and thus demand. This is only possible because of how much mark-up Lansheng and other distributors have taxed STAAR with since coming to market. Attached image shows comparable medtech products.
It's a fun question to think through- who has more leverage now that EVO is a recognized name through word of mouth? Can STAAR make up more of this 12K Yuan pie? Unit volumes don't have to increase at all to reflect a doubling of sales... Truly extraodinary to project the implications when combined when volumes do grow and more Chinese surgeons are trained...
5

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault27.jpg)